These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32058620)

  • 1. CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients.
    Waki K; Kawano K; Tsuda N; Komatsu N; Yamada A
    Cancer Sci; 2020 Apr; 111(4):1124-1131. PubMed ID: 32058620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients.
    Waki K; Yokomizo K; Kawano K; Tsuda N; Komatsu N; Yamada A
    Cancer Immunol Immunother; 2020 Oct; 69(10):2001-2007. PubMed ID: 32393999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
    Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T
    Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
    Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
    J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination.
    Noguchi M; Mine T; Komatsu N; Suekane S; Moriya F; Matsuoka K; Yutani S; Shichijo S; Yamada A; Toh U; Kawano K; Azuma K; Uemura H; Okuno K; Matsumoto K; Yanagimoto H; Yamanaka R; Oka M; Todo S; Sasada T; Itoh K
    Cancer Biol Ther; 2010 Dec; 10(12):1266-79. PubMed ID: 20935522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.
    Narita Y; Arakawa Y; Yamasaki F; Nishikawa R; Aoki T; Kanamori M; Nagane M; Kumabe T; Hirose Y; Ichikawa T; Kobayashi H; Fujimaki T; Goto H; Takeshima H; Ueba T; Abe H; Tamiya T; Sonoda Y; Natsume A; Kakuma T; Sugita Y; Komatsu N; Yamada A; Sasada T; Matsueda S; Shichijo S; Itoh K; Terasaki M
    Neuro Oncol; 2019 Feb; 21(3):348-359. PubMed ID: 30500939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.
    Kawano K; Tsuda N; Matsueda S; Sasada T; Watanabe N; Ushijima K; Yamaguchi T; Yokomine M; Itoh K; Yamada A; Kamura T
    Immunopharmacol Immunotoxicol; 2014 Jun; 36(3):224-36. PubMed ID: 24773550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.
    Shindo Y; Hazama S; Suzuki N; Iguchi H; Uesugi K; Tanaka H; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Takenouchi H; Matsui H; Kanekiyo S; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Fujita T; Kawakami Y; Nakamura Y; Oka M; Nagano H
    J Exp Clin Cancer Res; 2017 Feb; 36(1):36. PubMed ID: 28241889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
    Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
    Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.
    Kawano K; Tsuda N; Waki K; Matsueda S; Hata Y; Ushijima K; Itoh K; Yamada A; Kamura T
    Cancer Sci; 2015 Sep; 106(9):1111-7. PubMed ID: 26122553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.
    Nishida S; Morimoto S; Oji Y; Morita S; Shirakata T; Enomoto T; Tsuboi A; Ueda Y; Yoshino K; Shouq A; Kanegae M; Ohno S; Fujiki F; Nakajima H; Nakae Y; Nakata J; Hosen N; Kumanogoh A; Oka Y; Kimura T; Sugiyama H
    J Immunother; 2022 Jan; 45(1):56-66. PubMed ID: 34874330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
    Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
    J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
    Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
    Front Immunol; 2021; 12():691605. PubMed ID: 34484187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
    Terasaki M; Shibui S; Narita Y; Fujimaki T; Aoki T; Kajiwara K; Sawamura Y; Kurisu K; Mineta T; Yamada A; Itoh K
    J Clin Oncol; 2011 Jan; 29(3):337-44. PubMed ID: 21149665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
    Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
    Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum CD4 Is Associated with the Infiltration of CD4
    You Q; Fang T; Yin X; Wang Y; Yang Y; Zhang L; Xue Y
    J Immunol Res; 2021; 2021():6539702. PubMed ID: 34258299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer.
    Waki K; Kawano K; Tsuda N; Ushijima K; Itoh K; Yamada A
    J Immunol Res; 2017; 2017():1423683. PubMed ID: 28536706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.
    Matsumoto K; Noguchi M; Satoh T; Tabata K; Fujita T; Iwamura M; Yamada A; Komatsu N; Baba S; Itoh K
    BJU Int; 2011 Sep; 108(6):831-8. PubMed ID: 21166757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.
    Santin AD; Bellone S; Ravaggi A; Pecorelli S; Cannon MJ; Parham GP
    Obstet Gynecol; 2000 Sep; 96(3):422-30. PubMed ID: 10960637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy.
    Yacyshyn MB; Poppema S; Berg A; MacLean GD; Reddish MA; Meikle A; Longenecker BM
    Int J Cancer; 1995 May; 61(4):470-4. PubMed ID: 7538976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.